Physician profile
Jay Pepose
NPI 1134111446
$515,862.88
in general payments reported to CMS, 2019-2025
31 companies · $427K in 2025
The $427K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $11K · 2021: $9,959 · 2022: $15K · 2023: $8,560 · 2024: $722 · 2025: $427K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $411K · Travel and Lodging: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,700 · Food and Beverage: $4,026 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,226 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $410,558.14 |
| Travel and Lodging | $13,553.88 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,700.00 |
| Food and Beverage | $4,026.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,225.50 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $420,755.93 | 2023-2025 | Ryzumvi, Tyrvaya |
| Sun Pharmaceutical Industries INC. | $18,694.41 | 2019-2024 | Cequa |
| Kala Pharmaceuticals, INC. | $14,908.82 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14,334.97 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $14,090.21 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Shire North American Group INC | $7,023.40 | 2019 | |
| Glaxosmithkline, LLC. | $5,850.00 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $4,351.65 | 2019-2023 | Catalys System, Tecnis Iol |
| Genentech USA, INC. | $3,553.68 | 2019 | |
| Dompe US, INC. | $3,188.42 | 2019-2023 | Oxervate |
| Novartis Pharmaceuticals Corporation | $2,525.37 | 2020-2022 | |
| Tearlab Corp | $2,175.14 | 2019 | |
| Apellis Pharmaceuticals, INC. | $2,032.50 | 2025 | Syfovre |
| Alcon Vision LLC | $796.75 | 2019-2024 | Argos, Clareon, Simbrinza |
| Thea Pharma INC. | $390.77 | 2022-2025 | Iyuzeh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $235.68 | 2019 | |
| Harrow Eye, LLC | $174.09 | 2024 | |
| Abbvie INC. | $157.58 | 2022-2023 | |
| Biotissue Holdings INC. | $130.75 | 2019-2020 | |
| Allergan, INC. | $105.91 | 2020-2021 | |
| Glaukos Corporation | $105.35 | 2022-2023 | |
| Rxsight INC | $78.68 | 2020-2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $56.49 | 2024 | Xdemvy |
| Sight Sciences, INC. | $50.74 | 2022-2023 | Tearcare System |
| Rayner Intraocular Lenses Limited | $31.91 | 2022 | |
| Optos, INC. | $21.78 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $16.41 | 2021 | |
| Lensar, INC. | $6.09 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Pepose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.